Innate Immune Response Monitoring Via Monocyte HLA-DR in Severe Intra-abdominal Infections at Risk of Fungal Infection

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCentral Hospital, Nancy, France

About this trial

Intra-abdominal candidiasis (IAC) is a frequent and severe fungal infection in critically ill patients, often diagnosed late. Its pathophysiology remains unclear, particularly regarding why some patients develop invasive infection while others only show benign colonization. A potential explanation lies in the state of innate immunity. Monocyte HLA-DR expression, a recognized marker of immune suppression in critical care, may be transiently but profoundly reduced in non-immunocompromised patients who go on to develop IAC. This observational study aims to evaluate whether patients with IAC have greater innate immune dysfunction-assessed by HLA-DR expression-compared to those with severe bacterial intra-abdominal infections. The goal is to better understand the immune mechanisms involved and improve early risk stratification for IAC.

Eligibility criteria

Qualifiers

Adult patient (≥ 18 years old)

Patient admitted to the ICU or intermediate care unit for a severe intra-abdominal infection requiring urgent abdominal surgery

Abdominal surgery within the last 7 days

Supramesocolic gastrointestinal perforation

Disqualifiers

Radiologically guided drainage without surgery

Infected acute pancreatitis

Limitation or withdrawal of life-sustaining treatments

Moribund patient with an expected life expectancy < 48 hours

Trial design

Treatments tested in this trial

  • Immunomonitoring

Treatment groups

100 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Central Hospital, Nancy, France

Lead sponsor

Hospices Civils de Lyon

Collaborator